title: Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma.
abstract: Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma.
authors.affiliation: Department of Cell Biology and Anatomy, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX.
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.forename: Weiming
authors.initials: W
authors.lastname: Mao
keywords: glaucoma; intraocular pressure; preservative-free formulation; prostaglandin analog; tafluprost